Back to Media Coverage

INSIGHTEC’S EXABLATE CAN SPARE UTERUS DURING FIBROID TREATMENT: FDA

Lauren Dubinsky | October 9, 2015
icons for web-03.png

INSIGHTEC announced on Wednesday that the FDA has approved the relabeling of the ExAblate system to treat women with symptomatic uterine fibroids who want to spare their uterus and maintain fertility. ExAblate can now be used for both women who are “family complete” and those who still want to conceive.

 

Read more

Media Contacts:

Please fill in the following details and we will get in touch with you. (* Required)

agreement Error

Thank You!

Thank you for contacting us! We will get back to you shortly.

Thank You!

This site is brought to you by INSIGHTEC, © 2018 INSIGHTEC Ltd. All rights reserved.

NGSoft logo